Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

November 9, 2023

Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 2, 2023

Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

October 23, 2023

Harpoon Therapeutics Announces Up to $150 Million Private Placement

October 21, 2023

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

October 16, 2023

Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023

October 9, 2023

Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

September 28, 2023

Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting

September 15, 2023

Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort

September 13, 2023

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

September 6, 2023

Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2023. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations